MA MAXHEALTH
Max Healthcare Institute Q3 2025
MAMAXHEALTH

Max Healthcare Institute Q3 FY25 results (Oct–Dec 2024) and concall

Healthcare · Concall AI · Call held 31 Jan 2025

Management summary

  • Max Healthcare reported a strong Q3 FY25, achieving over 30% year-on-year growth in key financial metrics, significantly boosted by recent acquisitions and the rapid breakeven of its new Dwarka hospital.
  • The company continues its strategic expansion, including new asset-light projects in Thane and Mohali.
  • Actively progressing various brownfield and greenfield capacity additions..
  • Management also addressed pricing dynamics, particularly for institutional and insurance payors, and provided updates on its diverse business units.

Source: Inve concall analysis and management guidance record.

Highlights

  • Network gross revenue of Rs. 2,381 crores, up 34% YoY and 7% QoQ.

  • Network operating EBITDA of Rs. 622 crores, up 32% YoY and 10% QoQ.

  • Dwarka hospital achieved EBITDA breakeven in December 2024, a record 6 months from launch.

  • Max Lucknow reported 58% YoY revenue growth and 94% YoY EBITDA growth.

Why these two revenue figures differ: Management cited ₹2,381 Cr (Revenue) on the call, while the exchange-filed quarterly statement below reports ₹1,868 Cr — typically due to standalone vs. consolidated scope, revenue from operations vs. total income (including other income), or presentation adjustments.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25
Revenue1,868
EBITDA499
Net profit239
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Capacity

  • Mohali (Zirakpur) beds Capacity · High confidence 400 beds

    Previously 250 beds → 400 beds

  • Thane hospital commissioning Capacity · 2028 · High confidence 2028

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Flat QoQ revenue for existing units despite weak Q3 Direct
Q3 is typically a weak quarter because you have festivals in this quarter, and if you see the history, you will find that typically the revenues come down by 2-3% and EBITDA also drops by 3-4% in this quarter. Despite the history, this time it is flat and in fact the overall EBIT

Clarifies the seasonality of the business and highlights better-than-expected performance due to strong Diwali occupancy, indicating resilience.

Asked by Amey Chalke

Price increase for insurance schemes / institutional side Direct
We are not expecting a price increase on the insurance side, we were looking at a price increase on the institutional side. We are still expecting that as it is long overdue. Our belief is that it should come within a month or two. But let's see what happens on that. On the insur

Provides specific timelines and mechanisms for price adjustments, indicating potential for ARPOB improvement from institutional payors.

Asked by Amey Chalke

Unlock risks & concerns, Q4 FY25 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 2 risks, concerns & management red flags
  • 5 watchlist triggers for Q4 FY25
  • +17 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image